Nyxoah to attend Piper Sandler’s 36th Annual Healthcare Conference

Nyxoah will attend Piper Sandler 36^Th Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – 20 November 2024, 22:05 CET / 16:05 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company developing breakthrough treatment options for obstructive sleep apnea (OSA) through neuromodulation, announced today that the Company will participate in the Piper Sandler 36^Th Annual Healthcare Conference on Wednesday, December 4, 2024. The company is scheduled to present at 2:00 p.m. ET the same day via webcast.

A live audio broadcast of the presentation will be available online on the Investor Relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah
Nyxoah is reinventing sleep for the billion people who suffer from obstructive sleep apnea (OSA). We are a medical technology company developing ground-breaking treatment options for OSA through neuromodulation. Our first innovation is Genio®, a battery-free hypoglossal neuromodulation device that is inserted through a single incision under the chin and controlled by a wearable device. Through our commitment to innovation and clinical evidence, we have demonstrated best-in-class results in reducing the burden of OSA.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and Nasdaq in July 2021. Following the positive results of the BETTER SLEEP study, Nyxoah obtained CE-marked approval for the extension of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. The company also announced positive results from the pivotal DREAM IDE trial for FDA and US commercialization approval.

Caution – CE marked since 2019. Examination device in the USA. Restricted by US federal law to research purposes in the United States.

FORWARD-LOOKING STATEMENTS

Certain statements, beliefs and opinions in this press release are forward-looking and reflect Nyxoah’s current expectations and beliefs about the Genio® System; planned and ongoing clinical studies of the Genio® System; the potential benefits of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® System; the utility of clinical data to potentially obtain FDA approval of the Genio® System; and potential receipt of FDA approval and entry into the US market. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied in the forward-looking statements. These risks, uncertainties, assumptions and factors may adversely affect the outcome and financial effects of the plans and events described herein. In addition, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of Nyxoah’s Annual Report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission (“SEC “) on March 20, 2024 and subsequent reports that Nyxoah files with the SEC. A variety of factors including, but not limited to, changes in demand, competition and technology, could cause actual events, performance or results to differ materially from any anticipated development. Forward-looking statements in this press release regarding past trends or activities are not guarantees of future results and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements in this press release, those results or developments may not be indicative of results or developments in future periods. No representations or warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, Nyxoah expressly disclaims any obligation or undertaking to release any updates or revisions to the forward-looking statements contained in this press release as a result of changes in expectations or changes in events, conditions, assumptions or circumstances upon which these forward-looking statements are based, except as specifically required by law or regulation. Neither Nyxoah nor its advisors or representatives or any of its affiliates or any such person’s officers or employees warrant that the assumptions underlying such forward-looking statements are free from error, nor do they accept any responsibility for forward-looking statements. contained in this press release or the actual occurrence of the forecasted development. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:

Nyxoah
John Landry, CFO
[email protected]

For the media
In the United States
FINN Partners – Glenn Silver
[email protected]

In Belgium/France
Backstage Communication – Gunther De Backer
[email protected]

In International/Germany
MC Services – Anne Hennecke
[email protected]